<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00854854</url>
  </required_header>
  <id_info>
    <org_study_id>BX-TK-001</org_study_id>
    <nct_id>NCT00854854</nct_id>
  </id_info>
  <brief_title>Efficacy Study of TKcell in Advanced Gastric Cancer</brief_title>
  <official_title>Evaluating the Safety and Efficacy of Combination Therapy With FOLFOX-4 and TKcell Therapy Versus FOLFOX-4 Alone in Patients With Recurrent, Unresectable and Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Binex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Binex</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine efficacy of NKCell combined FOLFOX-4 chemotherapy&#xD;
      in gastric cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine response rate</measure>
    <time_frame>within study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine safety of combination,time to treatment failure, overall survival time</measure>
    <time_frame>within study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Oxaliplatin infusion (100mg/m2) on days 1 and 15 (every 2 weeks)&#xD;
5-FU bolus + infusions (400 mg/m2) on days 1, 2, 15 and 16&#xD;
LV infusions (200 mg/m2) on days 1, 2, 15 and 16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion of TKCell(autologous activated lymphocyte) over 2x10^9 cells, IV route, 7 times&#xD;
and chemotherapy schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TKCell</intervention_name>
    <description>TKCell 150ml IV for 7times after each FOLFOX-4 regimen :&#xD;
From the second cycle of FOLFOX4(start Day1),TKCell is administered in Day3 and Day8.In the third cycle of FOLFOX4(Day1),TKCell is administered in Day3 and Day8.In the fourth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the fifth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the sixth cycle of FOLFOX4(Day1),TKCell is administered in Day8</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>NKCell</other_name>
    <other_name>FOLFOX-4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Diagnosis of histologically confirmed adenocarcinoma of the gastric&#xD;
&#xD;
          -  ECOG performance status of 0 - 2&#xD;
&#xD;
          -  At least one definite measurable lesion(s): ≥ 1 cm on spiral CT scan or ≥2cm in&#xD;
             physical examination&#xD;
&#xD;
          -  Adequate liver, renal, bone marrow functions as evidence by the following; Absolute&#xD;
             neutrophil count &gt; 1.5 x 109/L; platelets &gt; 7.5 x 109/L; Bilirubin less than 2 mg/dL&#xD;
             ASAT and/or ALAT &lt; 5 UNL; serum creatinine ≤ 2 ULN&#xD;
&#xD;
          -  Minimum life expectancy of 12 weeks&#xD;
&#xD;
          -  Effective contraception for both male and female subjects if the risk of conception&#xD;
             exists&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Brain metastasis and/or leptomeningeal disease (known or suspected)&#xD;
&#xD;
          -  Previous chemotherapy for gastric cancer except adjuvant treatment with progression of&#xD;
             disease documented &gt; 6 months after end of adjuvant treatment.&#xD;
&#xD;
          -  Previous oxaliplatin-based chemotherapy&#xD;
&#xD;
          -  Surgery (excluding diagnostic biopsy) or irradiation within 4 weeks prior to&#xD;
             randomization and chemotherapy&#xD;
&#xD;
          -  HIV antibody (+), Chronic hepatitis&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Concurrent or previous chronic systemic immune therapy, targeted therapy, hormonal&#xD;
             therapy not indicated in the study protocol except for contraception&#xD;
&#xD;
          -  Clinically relevant coronary artery disease, history of myocardial infarction, high&#xD;
             risk of uncontrolled arrhythmia&#xD;
&#xD;
          -  Known hypersensitivity reaction to any of the components of the treatment.&#xD;
&#xD;
          -  Pregnancy (absence to be confirmed by ß-hCG test) or lactation period&#xD;
&#xD;
          -  Participation in another clinical study within the 30 days before randomization&#xD;
&#xD;
          -  Significant disease which, in the investigator's opinion, would exclude the subject&#xD;
             from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seok-Goo Cho, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The catholic University of korea</name>
      <address>
        <city>Banpo-Dong</city>
        <state>Seoul</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.bi-nex.com/</url>
    <description>Click here for more information about this study.</description>
  </link>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>February 27, 2009</study_first_submitted>
  <study_first_submitted_qc>March 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2009</study_first_posted>
  <last_update_submitted>May 15, 2009</last_update_submitted>
  <last_update_submitted_qc>May 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Park, Eun-Jin / RN</name_title>
    <organization>CRM(clinical research manager)</organization>
  </responsible_party>
  <keyword>NKCell</keyword>
  <keyword>FOLFOX-4</keyword>
  <keyword>gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

